Innovative Clinical Associates

Innovative Clinical Associates, based in Silver Spring, MD, is one of the SAMHSA-registered treatment programs operating in MD. The facility's programming is outpatient (Outpatient, MAT), not residential. What this page can help with is the frame — what to ask, what to verify, what to compare against.

Care levels at Innovative Clinical Associates

Innovative Clinical Associates is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. The useful move is to have an ASAM-aligned assessment done before admission — ideally by someone outside the facility's admissions team — to confirm that the level of care offered here is what the clinical picture calls for.

Insurance and payment

On insurance specifically: Innovative Clinical Associates accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Before admission, ask the facility's utilization-review team for a written Verification of Benefits — not verbal assurance, which is where most post-treatment financial surprises come from. Also ask for specific plan-level confirmation, not carrier-level (e.g., "your Aetna PPO plan" not just "Aetna").

Before you call

Before admission to Innovative Clinical Associates, three questions consistently produce the most useful information: (1) which ASAM level of care are you treating me at, and what is the clinical rationale; (2) can you send me a written Verification of Benefits for my specific insurance plan; (3) what is your policy on medication-assisted treatment for opioid use disorder — specifically, do you continue patients on buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.